Ovid Therapeutics (OVID) Assets Average (2017 - 2026)

Ovid Therapeutics (OVID) has reported Assets Average for 10 consecutive years, with $228.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 187.65% year-over-year to $228.8 million; the trailing twelve-month figure through Jun 2026 stood at $228.8 million (up 187.65% YoY), and the FY2025 full-year result was $121.6 million, up 2.92% from the prior year.
• Assets Average advanced to $228.8 million in Q2 2026 per OVID's latest filing, from $188.3 million in the prior quarter.
• Across five years, Assets Average topped out at $228.8 million in Q2 2026 and bottomed at $70.6 million in Q3 2025.
• Historically, Assets Average has averaged $138.6 million across 5 years, with a median of $136.2 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Assets Average tumbled 36.94% in 2025, then soared 187.65% in 2026.
• Over 5 years, Assets Average stood at $160.1 million in 2022, then slipped by 16.0% to $134.5 million in 2023, then dropped by 27.59% to $97.4 million in 2024, then climbed by 10.25% to $107.4 million in 2025, then soared by 113.05% to $228.8 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $228.8 million, $188.3 million, and $107.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.